U.S. Markets closed
  • S&P 500

    4,431.85
    +105.34 (+2.43%)
     
  • Dow 30

    34,725.47
    +564.69 (+1.65%)
     
  • Nasdaq

    13,770.57
    +417.79 (+3.13%)
     
  • Russell 2000

    1,968.51
    +37.22 (+1.93%)
     
  • Crude Oil

    87.29
    +0.68 (+0.79%)
     
  • Gold

    1,792.30
    -2.70 (-0.15%)
     
  • Silver

    22.49
    -0.19 (-0.82%)
     
  • EUR/USD

    1.1152
    +0.0005 (+0.0446%)
     
  • 10-Yr Bond

    1.7820
    -0.0250 (-1.38%)
     
  • Vix

    27.66
    -2.83 (-9.28%)
     
  • GBP/USD

    1.3401
    +0.0019 (+0.1447%)
     
  • USD/JPY

    115.1900
    -0.1120 (-0.0971%)
     
  • BTC-USD

    37,588.81
    +716.93 (+1.94%)
     
  • CMC Crypto 200

    863.83
    +21.37 (+2.54%)
     
  • FTSE 100

    7,466.07
    -88.24 (-1.17%)
     
  • Nikkei 225

    26,717.34
    +547.04 (+2.09%)
     

Teva/Mylan Deal Doesn’t Stir Pharma ETFs

On a down day for U.S. stocks, even the latest rumor of a mega pharmaceuticals deal is proving ineffective in propping up exchange traded funds tracking the industry.

Multiple media outlets are reporting that Israeli generic drug giant Teva Pharmaceuticals (TEVA) is mulling a bid for Mylan (MYL).

“Teva hasn’t made a formal approach yet, the people said, though Mylan is aware of the Israeli company’s interest. Teva is evaluating the purchase internally and has also approached advisers about the potential bid and financing, the people said, asking not to be identified discussing private information,” according to Bloomberg.

Last week, Mylan offered to acquire errigo (PRGO) for $205 per share, or $28.86 billion in an effort to form a global powerhouse in generic and specialty drugs as well as over-the-counter treatments. [Pharma ETFs Like Mylan-for-Perrigo News]

News of a potential Teva bid for Mylan has not been enough to lift the PowerShares Dynamic Pharmaceuticals Portfolio (PJP) , which is off 1.6% today. That $2 billion ETF allocates a combined 7.6% of its weight to Perrigo and Mylan.

One ETF with heavy Teva exposure that is trading modestly higher is the iShares MSCI Israel Capped ETF (EIS) . EIS had an almost 26% weight to Teva at the start of trading today.

EIS’ rival, the Market Vectors Israel ETF (ISRA) , is off by 1.5%. While both EIS and ISRA were boosted by news of Mylan’s bid for Perrigo, any ensuing Teva-for-Mylan drama is more pertinent to ISRA because that now has a 14.2% to Perrigo, making the stock the ETF’s largest holding. By comparison, Perrigo is not one of the 54 stocks held by Perrigo.

There is potentially more to the story for the Israel ETFs, particularly ISRA, which tracks the BlueStar Israel Global Index (BIGI). Although shares of Perrigo hover near Mylan’s $205 per share offer price, Perrigo management Perrigo management has yet to respond to the offer from Mylan. [Fab Pharma Focus for Israel ETFs]

“Cross-border M&A also performed well, reaching $315.2 billion–the highest Q1 volume since 2007 when activity reached $357.9 billion. The healthcare sector was the most targeted industry, with deal value of $126.5 billion,” according to Yardeni Research.

Market Vectors Israel ETF

isra
isra